ALFURO-DS (Cefuroxime Axetil 125 mg/5ml) is a second-generation cephalosporin antibiotic that offers a “Sure Win” in the treatment of infected zones. Specially formulated as an oral suspension for pediatric use, it provides a broad-spectrum defense against a wide array of bacterial pathogens, ensuring rapid recovery even in challenging clinical scenarios.
Advanced Clinical Profile
ALFURO-DS is engineered to overcome common bacterial defenses and deliver targeted therapeutic action:
Beta-Lactamase Resistance: It is highly resistant to most beta-lactamases, the enzymes often produced by bacteria to deactivate antibiotics. This ensures the medicine remains effective where other treatments might fail.
Comprehensive Activity: It is active against a wide range of both Gram-positive and Gram-negative organisms, providing versatile coverage for various bacterial strains.
Superior Penetration: ALFURO-DS attains high concentrations in the Cerebrospinal Fluid (C.S.F.), making it an invaluable tool in managing serious infections caused by H. influenzae, Meningococci, and Pneumococci.
Broad Therapeutic Applications
ALFURO-DS is indicated for a variety of acute and systemic infections, including:
Respiratory Tract Infections: Effective against Pharyngitis, Tonsillitis, and Acute Bacterial Maxillary Sinusitis.
Skin & Soft Tissue Infections (SSTI): A powerful solution for Impetigo and other acute skin infections.
Nosocomial & Surgical Infections: Trusted for managing hospital-acquired infections and surgical site prophylaxis.
Intrabdominal Infections: Indicated for Peritonitis, Cholecystitis, and Cholangitis.
Ear & Sinus Health: Rapidly addresses Acute Otitis Media.
Precision Pediatric Dosing
ALFURO-DS ensures safety and efficacy with a clear, weight-based dosing schedule for pediatric patients (aged 3 months to 12 years), typically administered twice daily (b.i.d.) for a period of 10 days:
Pharyngitis/Tonsillitis: 20 mg/kg/day
Acute Otitis Media / Sinusitis / Impetigo: 30 mg/kg/day
Why Doctors Trust ALFURO-DS
Healthcare professionals choose ALFURO-DS for its reliability in the “Infected Zone.” Its ability to reach high tissue concentrations, combined with its resistance to enzymatic degradation, makes it a cornerstone in pediatric antibiotic therapy. When the goal is a swift and certain resolution of infection, ALFURO-DS delivers the real power needed for total recovery.

-10%